Investors

Listed on the Canadian Securities Exchange (CSE): COOL & OTC Markets (OTC): CLABF. Frankfurt: LD62, WKN: A2P8K3

Highlights

Delivery system
  • Patent Pending Sublingual Transmucosal Thinstrip Technology
  • ¬†Administer Psychedelic Compounds, Delivery Mechanisms & Protocols, and Novel Drug Formulations.
R&D
  • Patent Pending Biosynthetic Psilocybin
  • *cGMP API Grade
  • Under One of Few Health Canada Licensed Dealer Labs

*Good Manufacturing Practices Active Pharmaceutical Ingredient

Clinics
  • Access To 200,000 + Patients
  • Advancement of Psychedelic Treatments through Clinical Research
  • Goal to Establish New Locations
Opportunity
  • Well Funded
  • $20M of Invested Capital
  • New Highly Experienced And Reputable Management Team

Trading Chart


Profile

CUSIP 21872J
ISIN CA21872J2083
Incorporated BC / Dec 3 2019
Fiscal Year End Dec 31
Industry Junior industrial

Consultants

Legal Counsel
Cassels
Auditor
Dale Matheson, Carr-Hilton Labonte LLP
Transfer Agent
Computershare Trust Company of Canada